# Impact of Combined Medication and Behavioral Treatment for ASD & ADHD

> **NCT03242772** · PHASE2 · TERMINATED · sponsor: **Duke University** · enrollment: 18 (actual)

## Conditions studied

- Autism Spectrum Disorder
- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Amphetamine
- **BEHAVIORAL:** ESDM informed parent coaching
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03242772
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-14
- **Primary completion:** 2020-12-28
- **Final completion:** 2021-04-19
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** The study stopped recruitment of new participants due to COVID. A substudy was developed with adaptations to the main design.
- **Last updated:** 2022-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03242772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03242772, "Impact of Combined Medication and Behavioral Treatment for ASD & ADHD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03242772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*